Rank | Name |
Company |
Base Salary ($000) | Bonus ($000) | Long-Term Compensation ($000) |
Other Annual Compensation ($000) |
Total Direct Cash Compensation ($000) | Cumulative Total Return ($) |
1 | Gordon M. Binder | Amgen Inc. | 799 |
638 |
8,864 |
242 | 10,543 |
153 |
2 |
Peter Johnson |
Agouron Pharmaceuticals Inc. (1) |
395 |
230 | 5,692 |
3 | 6,320 |
606 |
3 | Cam L. Garner | Dura Pharmaceuticals Inc. | 397 |
475 | 4,245 |
32 |
5,149 |
725 |
4 | Edward E. Penhoet (2) |
Chiron Corp. |
426 |
185 |
4,362 | 13 |
4,986 | 165 |
5 |
Sim Fass |
Bio-Technology General Corp. | 321 | 125 | 3,716 |
5 | 4,167 |
175 |
6 |
Timothy J. Barberich | Sepracor Inc. | 261 | 125 |
3,493 |
3 | 3,882 | 422 |
7 |
James P. Iuliano (3) | Molecular Devices Corp. | 193 | 60 | 2,898 |
2 | 3,153 |
187 |
8 |
John C. Martin | Gilead Sciences Inc. | 327 | 150 | 1,972 | 0 | 2,449 |
252 |
9 | Dinesh C. Patel (4) | TheraTech Inc. |
263 |
61 | 1,313 |
37 | 1,674 |
85 |
10 |
Henry Linsert Jr. (5,6) | Martek Bio-sciences Corp. | 218 | 0 | 1,355 | 0 | 1,573 | 159 |
NOTE: | ||||||||
* Unless otherwise noted, all compensation data reported are for the fiscal year ending Dec. 31, 1997. This ranking was compiled from a database containing detailed executive compensation data drawn from the proxy statements of 223 public biotechnology companies. | ||||||||
DEFINITION OF TERMS | ||||||||
BASE SALARY: Base salary earned in FY reported in proxy. Some salaries include deferred compensation, such as 401(k) contributions. | ||||||||
BONUS: Bonus earned in FY reported in proxy. | ||||||||
OTHER ANNUAL COMPENSATION: All cash compensation listed under columns "Other Compensation" and "Other Annual Compensation" in company proxy statements. Amounts include a wide variety of perquisites, among them auto allowances, fitness club dues, 401(k) corporate "matching" contributions, life insurance premiums, amounts contributed by companies to employee's accounts under retirement plans, loan forgivenesses and one-time relocation expenses. | ||||||||
LONG-TERM COMPENSATION: Includes gains from the exercise of stock options as reported in proxy statements. Does not include non-cash long-term compensation, namely option grants. | ||||||||
CUMULATIVE TOTAL RETURN: Taken from charts required by the SEC in proxy statements. Figure is calculated to represent a company's cumulative total shareholder return assuming $100 invested in the company's stock either on the IPO date (if less than five years ago) or for the last five years. | ||||||||
|
1.) Agouron Pharmaceuticals Inc.'s fiscal year ends June 30. On Jan. 26, 1999, Agouron announced a definitive agreement to be acquired by Warner-Lambert Co. 2.) On May 1, 1998, Edward E. Penhoet, a co-founder of Chiron and the company's CEO since its inception, assumed the title of vice chairman. Sean P. Lance was appointed president and CEO of Chiron, effective May 1, 1998. | ||||||||
3.) James P. Iuliano resigned from Molecular Devices Corp. on Oct. 13, 1997 however, he was paid his annual base salary through March 31, 1998. On March 11, 1998, Joseph D. Keegan was appointed as president and CEO of the company. His annual base salary will be $280,000, and he received a signing bonus of $150,000. | ||||||||
4.) TheraTech Inc. was acquired by Watson Pharmaceuticals Inc. on Jan. 18, 1999. | ||||||||
5.) Henry Linsert's long-term compensation in 1997 included $1,354,688 in value realized from the exercise of options to purchase 67,500 shares of common stock. The amount reported includes the exercise of options to purchase 67,500 shares during fiscal 1997 by a company wholly owned by Linsert and Martek CFO Steve Dubin, and through which Linsert and Dubin provided consulting services to Martek prior to accepting full-time positions with Martek. | ||||||||
6.) Martek Biosciences Corp.'s fiscal year ends Oct. 31. | ||||||||
